Key facts
- This page summarizes Joseph Romanelli's Form 4 filing for Merck & Co., Inc. (MRK).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 01 May 2025, 17:43.
Joseph Romanelli - 29 Apr 2025 Form 4 Insider Report for Merck & Co., Inc. (MRK)
- Reporting relationship
- President, Human Health Int?l
- Issuer ticker
- MRK
- Reported as of
- 29 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 May 2025, 17:43:06 UTC
- Prior SEC filing
- 06 Jan 2025
- Next SEC filing
- 02 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly E. W. Grez, attorney-in-fact for Joseph Romanelli
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph Romanelli filed Form 4 for Merck & Co., Inc. (MRK) on 01 May 2025.
Change
- Previous filing in this sequence was filed on 06 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRK
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 21,799
- Date
- 29 Apr 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRK
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +4,722
- Change %
- Price
- $0.000000
- Shares after
- 4,722
- Date
- 29 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,722
- Exercise price
- Footnotes
- F2, F3
MRK
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +9,444
- Change %
- Price
- $0.000000
- Shares after
- 9,444
- Date
- 29 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,444
- Exercise price
- Footnotes
- F2, F3
MRK
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +21,494
- Change %
- Price
- $0.000000
- Shares after
- 21,494
- Date
- 29 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,494
- Exercise price
- $84.71
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Holdings include shares acquired in dividend reinvestment transactions.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
Footnote F3
These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.
Footnote F4
The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.